The Role of C-Reactive Protein on the Long-Term Clinical Outcome after Primary or Rescue Percutaneous Coronary Intervention

Young Joon Hong; Myung Ho Jeong; Ok Young Park; Weon Kim; Ju Han Kim; Young Keun Ahn; Jeong Gwan Cho; Byoung Hee Ahn; Soon Pal Suh; Jong Chun Park; Sang Hyung Kim; Jung Chaee Kang

doi:10.3904/kjim.2003.18.1.29

Korean J Intern Med > Volume 18(1); 2003 > Article

Hong, Jeong, Park, Kim, Kim, Ahn, Cho, Ahn, Suh, Park, Kim, and Kang: The Role of C-Reactive Protein on the Long-Term Clinical Outcome after Primary or Rescue Percutaneous Coronary Intervention

Original Article

The Korean Journal of Internal Medicine 2003;18(1):29-34.

DOI: https://doi.org/10.3904/kjim.2003.18.1.29

The Role of C-Reactive Protein on the Long-Term Clinical Outcome after Primary or Rescue Percutaneous Coronary Intervention

Young Joon Hong, M.D., Myung Ho Jeong, M.D., Ph.D., Ok Young Park, M.D., Weon Kim, M.D., Ju Han Kim, M.D., Young Keun Ahn, M.D., Ph.D., Jeong Gwan Cho, M.D., Ph.D., Byoung Hee Ahn, M.D., Ph.D., Soon Pal Suh, M.D., Ph.D., Jong Chun Park, M.D., Ph.D., Sang Hyung Kim, M.D., Ph.D., Jung Chaee Kang, M.D., Ph.D.

The Heart Center of Chonnam National University Hospital, The Research Institute of Medical Sciences, Chonnam National University, Gwangju, Korea

Correspondence to : Myung Ho Jeong, M.D., Ph.D., FACC, FSCAI, Chief of Cardiovascular Medicine, Director of Cardiac Catheterization Laboratory, The Heart Center of Chonnam National University Hospital, 8 Hak-dong, Dong-gu, Gwangju 501-757, Korea. E-mail: myungho@chollian.net

Received October 31, 2002 Accepted January 13, 2003

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background

We examined the clinical and angiographic outcomes, success rate of the percutaneous coronary intervention (PCI) and long-term survival rate after primary or rescue PCI in patients with acute myocardial infarction (AMI) according to the level of the C-Reactive Protein (CRP) on admission.

Methods

Two hundred and eight consecutive patients with AMI who underwent primary or rescue PCI between 1997 and 1999 at Chonnam National University Hospital were divided into two groups: Group I (n=86, 59.9 ±9.3 years, male 74.4%) with a normal CRP (<1.0 mg/dL, mean value=0.43±0.14 mg/dL) on admission and Group II (n=122, 59.1±10.4 years, male 83.6%) with an elevated CRP (≥=1.0 mg/dL, mean value=3.50±0.93 mg/dL) on admission.

Results

There were no significant differences in the baseline characteristics noted between the two groups. The incidence of cardiogenic shock was higher in Group II than in Group I (Group I; 3/86, 3.5% vs. Group II; 15/122, 12.3%, p=0.026). The coronary angiographic findings did not differ between the two groups. The ejection fraction and Thrombolysis In Myocardial Infarction flow grade improved after PCI in both groups. The primary success rate of PCI was 94.2% (81/86) in Group I and 95.1% (116/122) in Group II (p=0.776). The survival rates for Group I were 97.7%, 97.7% and 96.5%, and those for Group II were 91.8%, 91.0% and 86.9% at 1, 6 and 12 months, respectively (p=0.043 at 1 month, p=0.040 at 6 months, p=0.018 at 12 months).

Conclusion

A high incidence of cardiogenic shock and worse long-term survival after PCI are observed in AMI patients with an elevated CRP.

Keywords: Myocardial infarction; Angioplasty; Shock; Prognosis

INTRODUCTION

Percutaneous coronary intervention (PCI) has been introduced as one of the effective methods in the treatment of acute myocardial infarction (AMI), and an understanding of the pathophysiologic changes involved in the underlying coronary arterial lesion after PCI may be important^{1, 2)}. An inflammatory reaction is one of the important pathologic findings in the atheromatous plaque of patients with acute coronary syndrome, and lymphocytes and monocytes/macrophages accumulate at the site of the plaque rupture^{3, 4)}.

One of the acute phase reactants, C-reactive protein (CRP), is synthesized in the liver by stimulation of cytokines, such as interleukin-6, and begins to elevate within 6 hours after stimulation of the liver by cytokine^{5, 6)}. The serum level of CRP reflects the overall systemic inflammatory reaction within the body and is a simple and objective index⁷⁾.

The level of CRP is closely related to atherosclerosis in coronary, cerebral and peripheral arteries⁸⁾. An increase in the serum CRP is known to relate with cardiovascular complications, such as sudden cardiac death or AMI⁹⁾. In the Multiple Risk Factor International Trial (MRFIT), the level of the CRP was significantly related with mortality due to coronary artery diseases¹⁰⁾.

The effects of the initial CRP level on the long-term mortality in patients with AMI, especially after primary or rescue PCI, have not been reported. Our study sought to observe the effects of the serum level of the CRP at the time of admission on the short- and long-term prognosis in patients with AMI after primary or rescue PCI, and the long-term prognosis in patients with AMI after primary or rescue PCI.

METHODS

1. Subjects

All consecutive patients with AMI, who were admitted and underwent primary or rescue PCI at The Heart Center of Chonnam National University Hospital between January 1997 and December 1999, were included in this study. All patients had chest pain for a duration of less than 6 hours and prolonged chest pain for more than 30 minutes not responsive to nitroglycerin or ST elevation of more than 1 mV in two or more limb leads or 2 mV in two consecutive precordial leads. Primary PCI was performed in 177 patients (59.4±9.7 years-old, M:F=141:36) and rescue PCI in 31 patients (59.7±11.4 years-old, M:F=25:6). The two hundred and eight patients were divided into two groups; Group I (n=86, 59.9±9.3 years-old, M:F=64:22, CRP less than 1 mg/dL) and Group II (n=122, 59.1±10.4 years-old, M:F=102:20, CRP higher than 1 mg/dL), and the clinical and angiographic characteristics, success rate of the PCI and the one-month, six-month and 12-month mortality were compared retrospectively between the two groups during a one-year clinical follow-up.

2. Laboratory and angiographic assessments

A blood sample was obtained on arrival at the emergency room and stored in a refrigerator. The serum level of the CRP was measured by the latex photometric immunoassay method, and 1 mg/dL was set as the cut-off value for the comparison between the high and low groups. The left ventricular ejection fraction was compared by the Simpson method using two-dimensional echocardiography. A coronary angiogram was performed through the femoral or radial arteries. Coronary artery lesions were classified using the American College of Cardiology/American Heart Association system, in which a stenosis of more than 75% defined as a significant lesion¹¹⁾. The lesion location, involved vessel number, lesion characteristics and presence of an intracoronary thrombus on the coronary angiogram were compared between the two groups, and the vessel patency of the infarct-related artery was assessed by the Thrombolysis in Myocardial Infarction (TIMI) flow score¹²⁾. TIMI 0 was defined as a total occlusion without any distal flow below the lesion, TIMI 1 as trivial distal flow without complete visualization of the entire artery, TIMI 2 as complete visualization of the entire coronary artery with a slow flow rate and TIMI 3 as complete visualization of the entire artery with a normal flow rate. Successful revascularization was defined as a TIMI flow score of more than grade 2 and residual stenosis less than 50%¹³⁾.

Rescue PCI was defined as a dilation of the occluded infarct-related artery less than 6 hours after the onset of chest pain in patients with persistent ST segment elevation and persistent chest pain after thrombolytic therapy. Urokinase or tissue plasminogen activator was used for thrombolysis and 100–300 mg of aspirin was administered daily. Heparin was administered to maintain an activated partial thromboplastin time of about 2 times above the normal control. After discharge from the hospital, the patients were observed at the out-patient clinic at 4 week intervals, and the cardiovascular mortality was assessed at 1, 6 and 12 months after the PCI. Restenosis was defined as diameter stenosis more than 50% by the Phillips quantitative coronary angiogram analysis system.

3. Statistical analysis

For the statistical analysis, the unpaired t-test, Chi-square test and multiple logistic regression analysis were performed using SPSS-PC 10.0 (Statistical package for the social sciences, SPSS Inc. Chicago, IL, U.S.A.) and MS Windows®, and the results were designated as mean±standard deviation. A value of p less than 0.05 was considered as significant.

RESULTS

1. Clinical characteristics

The age and sex ratios did not differ between the two groups (p=0.599, 0.104 respectively). There were no differences in these risk factors between the two groups (p=0.472, 0.373, 0.054 and 0.346, respectively) (Table 1). The incidence of cardiogenic shock was 3 cases in Group I (3.5%) and 15 in Group II (12.3%), and was higher in Group II than in group I (p=0.026) (Table 1). The values of Troponin I and T and ESR were higher than those in Group I (p<0.001, <0.001 and =0.026, respectively) (Table 1).

2. Coronary angiographic characteristics

The time interval between the onset of symptoms and arrival at the emergency room, and the interval between the onset of symptoms and the time of the PCI did not differ between the two groups (p=0.860 and 0.843, respectively) (Table 1). The number of patients that underwent rescue PCI or primary PCI did not differ between the two groups (p=0.747) (Table 1). The number of vessels involved on diagnostic coronary angiography did not differ between the two groups (p=0.753) (Table 2). The mean number of vessels involved was 1.60±0.71 in group I and 1.54±0.71 in group II. The order of frequency in the number of vessels involved was single vessel disease, two vessel disease and three vessel disease.

Lesions involving the left anterior descending artery were the most common, but the lesion distribution did not differ between the two groups (p=0.642) (Table 2). The lesion morphology assessed according to the ACC/AHA classification was not significantly different between the two groups (p=0.634) (Table 2). An intracoronary thrombus was not different between the two groups (p=0.450) (Table 2). The mean TIMI flow grade did not differ between the two groups (p=0.087) (Table 2).

3. Results of PCI

The mean TIMI flow grade represented a significant improvement after the PCI (p<0.001) (Table 4), and there was no significant difference between the two groups (p=0.863) (Table 3). The primary success rate resulted in no difference between the two groups (p=0.776) (Table 3).

4. Left ventricular ejection fraction

The ejection fraction measured by two-dimensional echocardiography on admission did not differ between the two groups (p=0.673) (Table 1). After the PCI, the ejection fraction significantly improved in both groups (p<0.001) (Table 4).

5. Major adverse cardiac events and the long-term survival

The in-hospital death at the time of admission that presented with cardiogenic shock occurred in 2 cases in group I and 7 cases in group II. Major adverse cardiac events were observed in all patients at one, six and twelve months. Restenosis represented a significantly higher occurrence in group II (p=0.009) and the number of cases with target lesion revascularization was higher in group II (p=0.017) (Table 5).

The survival rate was analyzed during the clinical follow-up at 1, 6 and 12 months after the PCI and the survival rate was significantly lower in group II than in group I for each time period (p=0.043, 0.040 and 0.018, respectively) (Table 3).

6. Independent predictive factors for the one-year mortality

Multiple logistic regression analysis was performed for the prediction of the one-year mortality after primary or rescue PCI. Cardiogenic shock at the time of admission, a CRP higher than 1 mg/dL and an ejection fraction lower than 40% after the PCI were independent risk factors (p<0.001, 0.001 and 0.043, respectively), whereas cardiac tropanin-T was a strong albeit not independent predictor indicating a one-year mortality. Age, sex, risk factors for atherosclerosis, target lesion location, involved vessel number and TIMI flow grade were not independent risk factors (Table 6).

DISCUSSION

Our study demonstrated that the event-free survival was higher in patients with AMI and high CRP after primary or rescue PCI. The mechanism of the inflammatory reaction in acute myocardial infarction has not been clearly elucidated¹⁴⁾, but previous reports suggested that the level of CRP is elevated in patients with acute myocardial infarction and that CRP is an important factor for the prediction of the short-and long-term prognosis in acute myocardial infarction^15–18). CRP is produced from liver cells stimulated by cytokines, such as interleukin-6 (IL-6), tumor necrosis factor (TNF)-α and interieukin-1 (IL-1), and these kinds of cytokines are released from activated monocytes/macrophages during ischemic insults in patients with an acute myocardial infarction¹⁹⁾. A recent study reported that the concentration of IL-6 was closely related to the level of CRP in an acute myocardial infarction²⁰⁾. Our results suggested that elevated CRP could predict poor prognosis even after successful PCI in patients with AMI.

The level of CRP at the time of admission in patients with an acute myocardial infarction can be used as a useful index for the assessment of the vulnerability of the coronary artery lesion. Tomoda et al.²¹⁾ reported that a level of CRP greater than 0.3 mg/dL in patients with an acute myocardial infarction was related to the restenosis after the primary PCI, restenosis, recurrent myocardial infarction and cardiac death. In contrast, in the patients with a normal CRP on admission, major adverse cardiac events were demonstrated in less than 5% of the patients.

Our study demonstrated that lower event-free survival at one, six and twelve months after the PCI was observed in patients with a CRP higher than 1 mg/dL. Our preliminary study²²⁾ showed that the mean value of CRP was elevated in Asian patients with an acute myocardial infarction. Liuzzo et al.²³⁾ reported that the serum concentration of CRP was elevated after PCI in patients with a high CRP, but not so in patients with a normal baseline CRP or in patients with stable angina. Zebrack et al.²⁴⁾ reported that pre-discharge CRP levels are higher after acute myocardial infarction than after unstable angina or stable angina and that CRP is strongly predictive of long-term risk of death or nonfatal acute myocardial infarction for unstable angina or stable angina, but it is not predictive shortly after acute myocardial infarction.

Nikfardjam et al.²⁵⁾ reported that high CRP level was associated with increased 3-year mortality, but there was only a weak and non-significant association between increased serum CRP and the risk of death. Walter et al.²⁶⁾ reported that high CRP level was independently associated with a high risk of adverse coronary events and that restenosis rates were significantly higher in the two upper tertiles compared with CRP levels in the lowest tertiles. Abdelmouttaleb et al.²⁷⁾ analyzed 201 patients who underwent diagnostic coronary angiography, 142 patients with coronary artery stenosis, 37 patients without lesions and 37 controls. The serum level of the CRP was closely related to the acute coronary syndrome. Tomoda et al.²¹⁾ reported that CRP was the only prognostic factor in patients with an acute myocardial infarction for the prediction of major adverse cardiac events (MACE), such as recurrent myocardial infarction, target lesion revascularization due to restenosis and cardiac death. Anzai et al.²⁸⁾ reported that a peak CRP level of more than 2.0 mg/dL and an age greater than 70 years old were predictive factors for MACE during a one-year clinical follow-up. Giannitsis et al.²⁹⁾ reported that the prognostic factors for long-term cardiac death in patients with an acute myocardial infarction were cardiogenic shock and elderly patients older than 75 year of age.

However, this was a single center study and the major limitation was the sample size of the number of AMI cases that underwent primary or rescue PCI. Further, patients with cardiogenic shock should be divided into a separate group in future studies with a large number of patients.

In conclusion, an elevated CRP is an independent prognostic marker in patients with acute myocardial infarction after primary or rescue PCI.

Table 1.

Baseline clinical characteristics

	Group I (n=86)	Group II (n=122)	p-value
CRP (mg/dL)	0.43±0.14	3.50±1.93	<0.001
Age (yr)	59.9±9.3	59.1±10.4	0.599
Male (%)	64 (74.4)	102 (83.6)	0.104
Risk factors (%)
Hypertension	31 (36.0)	50 (41.0)	0.472
Diabetes mellitus	16 (18.6)	29 (23.8)	0.373
Smoking	38 (44.2)	62 (50.8)	0.346
hyperlipidemia	31 (36.0)	29 (23.8)	0.054
Troponin-I (ng/mL)	20.6±37.7	79.2±70.2	<0.001
Troponin-T (ng/mL)	0.55±0.71	2.87±2.40	<0.001
ESR (mg/dL)	9.9±12.6	16.7±27.8	0.022
Shock on admission (%)	3 (3.5)	15 (12.3)	0.026
Baseline ejection fraction (%)	49.4±10.5	50.1±11.2	0.673
Percutaneous coronary intervention (%)			0.747
Rescue PCI	12 (14.0)	19 (15.6)
Primary PCI	74 (86.0)	103 (84.4)
Time from pain to admission (min)	195±120	200±117	0.860
Time from pain to PCI (min)	278±99	282±101	0.843

CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; PCI, percutaneous coronary intervention

Table 2.

Coronary angiographic findings

	Group I (n=86)	Group II (n=122)	p-value
Number of involved vessels (%)			0.753
One	45 (52.3)	70 (57.4)
Two	30 (34.9)	37 (30.3)
Three	11 (12.8)	15 (12.3)
Mean No.	1.60±0.71	1.54±0.71
Target coronary artery (%)			0.642
Left anterior descending artery	41 (47.7)	64 (52.5)
Left circumflex artery	5 (5.8)	9 (7.4)
Right coronary artery	40 (46.5)	49 (40.2)
ACC/AHA classification (%)			0.634
Type A	2 (2.3)	6 (4.9)
Type B₁	41 (47.7)	64 (52.5)
Type B₂	19 (22.1)	23 (18.9)
Type C	24 (27.9)	29 (23.8)
Intra-coronary thrombosis (%)	16 (18.6)	28 (23.0)	0.450
TIM I flow (%)			0.087
0	24 (27.9)	36 (29.5)
1	13 (15.1)	7 (5.7)
2	29 (33.7)	55 (45.1)
3	20 (23.3)	24 (19.7)
Mean TIMI flow	1.28±0.82	0.92±1.04

ACC/AHA, American College of Cardiology/American Heart Association; TIMI, Thrombolysis In Myocardial Infarction

Table 3.

Results after percutaenous coronary intervention

	Group I (n=86)	Group II (n=122)	p-value
Post-PCI TIMI flow (%)			0.863
0	0 (0.0)	0 (0.0)
1	5 (5.8)	6 (4.9)
2	10 (11.6)	17 (13.9)
3	71 (82.6)	99 (81.1)
Mean TIMI flow	2.77±0.55	2.77±0.53
Primary success rate (%)	81 (94.2)	116 (95.1)	0.776
Ejection fraction after PCI (%)	52.0±9.0	52.7±9.7	0.553
Survival (%)
1 month	84 (97.7)	112 (91.8)	0.043
6 months	84 (97.7)	111 (91.0)	0.040
12 months	83 (96.5)	106 (86.9)	0.018

TIMI, Thrombolysis In Myocardial Infarction; PCI, percutaneous coronary intervention

Table 4.

Improvement of the ejection fraction and Thrombolysis In Myocardial Infarction flow after percutaneous coronary intervention

	EF (%)	EF after PCI (%)	p-value
Normal CRP (n=86)	49.4±10.5	52.0±9.0	<0.001
High CRP (n=122)	50.1±11.2	52.7±9.7	<0.001
	TIMI	TIMI after PCI
Normal CRP (n=86)	1.52±1.13	2.77±0.55	<0.001
High CRP (n=122)	1.55±1.11	2.76±0.53	<0.001

EF, ejection fraction; PCI, percutaneous coronary intervention; CRP, C-reactive protein; TIMI, Thrombolysis In Myocardial Infarction

Table 5.

Adverse clinical events

	Group I (n=86)	Group II (n=122)	p-value
In-hospital events (%)
Reinfarction	2 (2.3)	4 (3.3)	0.687
Target vessel revascularization	4 (4.7)	10 (8.2)	0.043
Death	2 (2.3)	9 (7.4)	0.040
MACE	8 (9.3)	23 (18.9)	0.021
Follow-up events at 1 year (%)
Restenosis	13 (15.1)	35 (28.7)	0.009
Target vessel revascularization	10 (11.6)	29 (23.8)	0.017
Death	3 (3.5)	16 (13.1)	0.019

MACE, major adverse cardiac events

Table 6.

Multiple logistic regression analysis for the prediction of the one-year mortality

Variables	Odds ratio	95% Cl	p-value
Cardiogenic shock	9.11	4.10–30.67	<0.001
CRP on admission	8.21	2.54–20.14	0.001
Post-PCI EF	4.65	1.70–10.89	0.046
Admission cTnT (≥0.1 vs <0.1 ng/dL)	4.49	0.82–10.84	0.098
Hypertension	2.14	0.30–10.10	0.287
Target artery	1.20	0.52–2.30	0.511
No. of vessels involved	1.32	0.51–4.19	0.409
Initial TIMI flow	1.44	0.59–3.81	0.267
Post-PCI TIMI flow	1.91	0.56–7.11	0.308
Initial ejection fraction	1.13	1.0 –1.3	0.098

CRP, C-reactive protein; PCI, percutaneous coronary intervention; EF, ejection fraction; cTnT, cardiac troponin-T; TIMI, Thrombolysis In Myocardial infarction

REFERENCES

1. Grines CL, Browne KF, Marco J, Rothbaum D, Stone GW, O’Keefe J, Overlie P, Donohue B, Chelliah N, Timmis GC for the Primary Angioplasty in Myocardial Infarction Study Group. A comparison of immediate angioplasty with thrombolytic therapy for acute myocardial infarction. N Engl J Med 28:673–6791993.

2. Stone GW, Brodie BR, Griffin JJ, Costantini C, Morice MC, St Goar FG, Overlie PA, Popma JJ, McDonnell J, Jones D, O’Neill WW, Grines CL for the PAMI Stent Pilot Trial Investigators. Clinical and angiographic follow-up after primary stenting in acute myocardial infarction. The Primary Angioplasty in Myocardial Infarction (PAMI) Stent Pilot Trial. Circulation 99:1548–15541999.

3. van der Wal AC, Becker AE, van der Loos CM, Das PK. Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology. Circulation 89:36–441994.

4. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 362:801. 1993.

5. Morrone G, Ciliberto G, Oliviero S, Arcone R, Dente L, Content J, Cortese R. Recombinant interleukin 6 regulates the transcriptional activation of a set of human acute phase genes. J Biol Chem 263:12554–125581988.

6. Le JM, Vilcek J. Interleukin 6: a multifunctional cytokine regulating immune reactions and the acute phase protein response. Lab Invest 61:588–6021989.

7. Pepys MB. The acute phase response and C-reactive protein. In: Weatherall DJ, Ledingham JGG, Warrell DA, eds. Oxford textbook of medicine. third edition. Oxford: Oxford University Press, 1527. 1995.

8. Heinrich J, Schulte H, Schonfeld R, Kohler E, Assmann G. Association of variables of coagulation, fibrinolysis and acute-phase with atherosclerosis in coronary and peripheral arteries and those arteries supplying the brain. Thromb Haemost 73:374–3791995.

9. Thompson SG, Kienast J, Pyke SD, Haverkate F, van de Loo JC. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. N Engl J Med 332:635–6411995.

10. Kuller LH, Tracy RP, Shaten J, Meilahn EN. Relation of C-reactive protein and coronary heart disease in the MRFIT nested case-control study. Am J Epidemiol 144:537–5471996.

11. Austen WG, Edwards JE, Frye RL, Gensini GG, Gott VL, Griffith LS, McGoon DC, Murphy ML, Roe BB. A reporting system on patients evaluated for coronary artery disease. Circulation 51:7–401975.

12. Gibson CM, Cannon CP, Daley WL, Dodge JT Jr, Alexander B Jr, Marble SJ, McCabe CH, Raymond L, Fortin T, Poole WK, Braunwald E for the TIMI 4 study group. TIMI frame count: a quantitative method of assessing coronary artery flow. Circulation 93:879–8881996.

13. The TIMI Study Group. The thrombolysis in myocardial infarction trial. N Engl J Med 312:932–9361985.

14. Mehta JL, Saldeen TGP, Rand K. Interactive role of infection, inflammation and traditional risk factors in atherosclerosis and coronary artery disease. J Am Coll Cardiol 31:1217–12251998.

15. Voulgari F, Cummins P, Gardecki TI, Beeching NJ, Stone PC, Stuart J. Serum levels of acute phase and cardiac proteins after myocardial infarction, surgery and infection. Br Heart J 48:352–3561982.

16. Gram J, Kluft C, Jespersen J. Depression of tissue plasminogen activator (t-PA) activity and rise of t-PA inhibition and acute phase reactants in blood of patients with acute myocardial infarction (AMI). Thromb Haemost 58:817–8211987.

17. Mollnes TE, Tambs KE, Myreng Y, Engebresten LF. Acute phase reactants and complement activation in patients with acute myocardial infarction (AMD. Comple- ment 5:33–391988.

18. Haq M, Haq S, Tutt P, Crook M. Serum total sialic acid and lipid-associated sialic acid in normal individuals and patients with myocardial infarction, and their relationship to acute phase proteins. Ann Clin Biochem 30:383–3861993.

19. Dinarello CA. Interleukin-6 and the pathogenesis of the acute-phase response. N Engl J Med 311:1413. 1984.

20. Miyao Y, Yasue H, Ogawa H, Misumi I, Masuda T, Sakamoto T, Morita E. Elevated plasma interleukin-6 level in patients with acute myocardial infarction. Am Heart J 126:1299–13041993.

21. Tomoda H, Aoki N. Prognostic value of C-reactive protein levels within six hours after the onset of acute myocardial infarction. Am Heart J 140:324. 2000.

22. Kim KH, Jeong MH, Shin JH, Joo SB, Kim W, Lee SW, Kim KH, Kim NH, Cho JH, Park JC, Ahn YK, Na KJ, Cho JG, Ahn BH, Park JC, Kang JC. The role of chronic infection and inflammation to coronary artery disease in Korean patients with coronary artery disease. Korean Circulation J 30:1107–11162000.

23. Liuzzo G, Buffon A, Biasucci LM, Gallimore JR, Caligiuri G, Vitelli A, Altamura S, Ciliberto G, Rebuzzi AG, Crea F, Pepys MB, Maseri A. Enhanced inflammatory response to coronary angioplasty in patients with severe unstable angina. Circulation 98:2370–23761998.

24. Zebrack JS, Anderson JL, Maycock CA, Horne BD, Bair TL, Muhlestein JB, The Intermountain Heart Collaborative (IHC) Study Group. Usefulness of high-sensitivity C-reactive protein in predicting long-term risk of death or acute myocardial infarction in patients with unstable or stable angina pectoris or acute myocardial infarction. Am J Cardiol 89:145–1492002.

25. Nikfardjam M, Mullner M, Schreiber W, Oschatz E, Exner M, Domanovits H, Laggner AN, Huber K. The association between C-reactive protein on admission and mortality in patients with acute myocardial infarction. J Intern Med 247:341–3452000.

26. Walter DH, Fichtlscherer S, Sellwig M, Auch-Schwelk W, Schachinger V, Zeiher AM. Preprocedural C-reactive protein levels and cardiovascular events after coronary stent implantation. J Am Coll Cardiol 37:839–8462001.

27. Abdelmouttaleb I, Danchin N, Ilardo C, Aimone-Gastin I, Angioi M, Lozniewski A, Loubinoux J, Le Faou A, Gueant JL. C-reactive protein and coronary artery disease: Additional evidence of the implication of an inflammatory process in acute coronary syndromes. Am Heart J 137:346–3511999.

28. Giannitsis E, Lehrke S, Wiegand UK, Kurwski J, Muller-Bardorff M, Weidtman B, Richardt G, Katus HA, Anzai T, Yoshikawa T, Shiraki H, Asakura Y, Akaishi M, Mitamura H, Ogawa S. C-reactive protein as a predictor of infarct expansion and cardiac rupture after a first Q-wave acute myocardial infarction. Circulation 96:778–7841997.

29. Giannitsis E, Lehrke S, Wiegand UK, Kurowski J, Muller-Bardoff M, Weidtmann B, Richardt G, Katus HA. Risk stratification in patients with inferior acute myocardial infarction treated by percutaneous coronary intervention: The role of admission troponin-T. Circulation 102:2038–20442000.